THE RATIONALE FOR A COMPLETE AND PROMPT CHANGE OF THE BOARD AT HMA

AUGUST 2013
### SUMMARY OF PROCESS TO REVITALIZE HMA

<table>
<thead>
<tr>
<th>June 25</th>
<th>Glenview files consent solicitation documents with SEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 18</td>
<td>Record date</td>
</tr>
<tr>
<td>July 19</td>
<td>Consent solicitation commences with first votes cast</td>
</tr>
<tr>
<td></td>
<td><strong>Voting is continuous and open – the Board change is authorized as soon as consents from 50% plus 1 share are delivered to HMA to replace and refresh the Board</strong></td>
</tr>
<tr>
<td>July 25</td>
<td>HMA Board releases presentation expressing confidence in the performance of management and the Board, strong operational performance and the benefits of healthcare reform</td>
</tr>
<tr>
<td>July 30</td>
<td>5 days later, HMA announces:</td>
</tr>
<tr>
<td></td>
<td>1. A proposed sale of HMA to Community Health Systems (“Community”), subject to approval from regulators and 70% of HMA shareholders</td>
</tr>
<tr>
<td></td>
<td>2. Q2 results well below expectations, with Adjusted EBITDA and EPS falling 18% and 50% below consensus</td>
</tr>
<tr>
<td></td>
<td>3. Materially reduced 2013 Guidance, reducing EBITDA and EPS by 12% and 29%, respectively</td>
</tr>
<tr>
<td></td>
<td>• These represent the 3rd straight earnings miss and 2nd consecutive reduction in 2013 guidance</td>
</tr>
<tr>
<td></td>
<td>• HMA’s 2013 vs. 2012 EBITDA performance of -9% y/y is meaningfully below the peer average of +2% y/y (^1)</td>
</tr>
<tr>
<td></td>
<td>4. Consistent with a limited outside talent pool to recruit from, as well as the proposed sale to Community, names an internal divisional president with no prior public company leadership experience to interim president and CEO</td>
</tr>
<tr>
<td></td>
<td>5. The receipt of 4 additional subpoenas regarding compliance and regulatory matters</td>
</tr>
<tr>
<td></td>
<td><strong>Despite the significant nature of these announcements, the company has held no public conference calls and has allowed for no public question and answer sessions</strong></td>
</tr>
<tr>
<td>July 30</td>
<td>Glenview confirms it will move forward with its efforts to Revitalize HMA</td>
</tr>
<tr>
<td>July 31-August 2</td>
<td>HMA chooses to meet individually with select shareholders rather than hold a public conference call with public analyst Q&amp;A as is typical</td>
</tr>
</tbody>
</table>

\(^1\) 2013 based on midpoint of guidance range. Peer index includes CYH, HCA, LPNT, THC, and UHS.
**TWO SEPARATE & DISTINCT VOTES FOR HMA SHAREHOLDERS**

_The vote to replace and refresh the Board of HMA is separate and distinct from the vote regarding the Community Proposal that will come in several months_

### VOTE 1

**Revitalize HMA**  
**August 2013**

<table>
<thead>
<tr>
<th><strong>The Glenview Consent Solicitation to Revitalize HMA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Who votes:</strong></td>
</tr>
<tr>
<td><strong>Voting threshold:</strong></td>
</tr>
<tr>
<td><strong>Deadline:</strong></td>
</tr>
</tbody>
</table>

**Glenview recommends shareholders vote promptly to enable the Fresh Alternative Board to begin their important work**

**Key Considerations:**  
- Which Board is best equipped to:  
  - Stabilize and improve operations?  
  - Preserve and strengthen the consideration paid in the Community Proposal?  
  - Move HMA constructively forward from a regulatory and compliance perspective?  
  - Provide reliable transparency so that shareholders may make a well informed decision?  
  - Scope and assess ideas for value creation?

### VOTE 2

**Community Proposal**  
**Approximately December 2013**

<table>
<thead>
<tr>
<th><strong>Shareholders Vote to Accept or Reject the Community Acquisition Proposal</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Who votes:</strong></td>
</tr>
<tr>
<td><strong>Voting threshold:</strong></td>
</tr>
<tr>
<td><strong>Key Considerations:</strong></td>
</tr>
</tbody>
</table>

**Regardless of which board shareholders choose, the Community Proposal will be put to a shareholder vote so all holders of record may decide the merits of selling the company**

---

1 The date of the vote will be established by the Board of HMA in accordance with the terms of the Community Proposal. We believe that based upon the timeline for closing established in the announcement of the Community Proposal that a shareholder vote is likely to fall in the November to February timeframe – December is used for illustrative purposes.
**Building Value at HMA**

**Value Equation:**

- **Sitting Board**
  - Independent Value: Declined to $8.23, per HMA Board
  - + Synergies: $150-180 million
  - = Private Market Value: $13.78 + CVR

- **Fresh Alternative**
  - Are there identifiable improvements?
  - + Are these comprehensive?
  - = Is this full and fair PMV?

- We believe every company has two values:
  - Its *independent value*, based upon the value of its earnings, cash flows and net assets as a stand-alone company, and
  - Its *private market value* based upon the sum of its independent value plus a share of the synergies that could be created by combining with another, similar company

- The two values are inextricably linked and proportional – the stronger the value of the Company independently, the higher its private market value

- The sitting Board of HMA has informed shareholders that as a result of the decline in profitability under their direction in 2013, the independent value of the Company has dropped from $11.04 to $8.23

- As a result, the HMA Board has therefore decided to approve the deal with Community, which represents a 65% premium to their view of HMA’s independent value according to their presentation

---

*We believe we must replace the Board promptly to strengthen and secure the Community Proposal and to enhance investor understanding and confidence*

---

1 Per HMA Board presentation, “Creating Shareholder Value”, filed July 31, 2013, p. 15
2 Per CYH / HMA merger presentation filed July 30, 2013.
The Value of the Community Proposal is Enhanced by Revitalizing HMA

The Community Proposal offers three sources of value:

1. $10.50 in cash

2. $3.28 in CYH stock

3. $0-$1.00 in a CVR

Total = $13.78 + CVR

Revitalizing HMA would enhance this proposal

- Fixed

- Floating proportionally to Community’s stock price
  - Community’s stock should be higher, and therefore the value HMA shareholders receive will be greater if HMA is healthier at the time of transaction closing

- Floating proportionally to the expenses and cost to settle outstanding regulatory claims

- With respect to the CVR, we believe regulatory authorities may demand a smaller financial penalty if HMA has demonstrated a clear change in its compliance culture and approach

- Total value of Community Proposal

We believe the two variable sources of consideration (CYH stock and CVR payment) would be enhanced by the involvement and oversight of the Fresh Alternative Board and an engaged Alvarez & Marsal management team
The August Vote: A Comparison of Results & Capabilities of Each Board

Under Sitting Board

- 9% Y/Y EBITDA decline\(^1\)
- 30% Y/Y Earnings decline\(^1\)
- 25% decline in “independent value”\(^2\)

HMA Financial Health

HMA Regulatory Challenges

- 4 additional subpoenas in the past two months
- Extensive and expensive legal expenditures

Fresh Alternative

Awaiting Your Consent to Begin Work

- Actively engaged and energized Board and Interim Management
- Four turnaround experts on the Board
- Seasoned financial executives with proven track records of value creation

- Changing the Board demonstrates complete culture change to regulators
- Two of the finest experts in healthcare compliance on the Board
- A fresh and modern approach to quality and compliance

Strategic Alternatives

- Independent value $8.23 per HMA Board\(^2\)
- Value established in duress

- Prepared to identify, scope and communicate building blocks of performance improvement
- Commitment to provide transparent, unbiased financial information necessary for shareholder review

For these reasons, we believe that the odds that non-Glenview shareholders support a combination of HMA and Community are increased by changing the Board

\(^1\) 2013 based on the midpoint of HMA’s guidance ranges provided in July 30, 2013 filing
\(^2\) Per HMA’s Board presentation, “Creating Shareholder Value”, filed July 31, 2013, p. 15
If the Company was sold and a Strategic Review is complete, why change the Board now?

1. Preserve and strengthen the current Community Proposal
   - Enhanced energy, focus and capabilities to reverse financial decline and avoid material adverse change
   - Improve financial and operational health of HMA so that its value to Community is maximized, thereby strengthening the value of the equity component of the transaction
   - Attempt to minimize financial costs of regulatory overhang with a fresh approach

2. Ensure shareholders have all appropriate information to make an informed decision on the Community Proposal
   - Such information may include estimates of the earnings power of HMA and an assessment of synergy opportunities available in a transaction with Community
   - Significantly strengthen the financial reporting and shareholder communication function

3. Begin to build independent value of HMA during the period of regulatory review and shareholder evaluation to minimize risk to shareholders should the Community Proposal fail to receive the required approvals necessary for closing
   - Enhanced focus on cost containment, quality and admissions growth
   - Review and potentially accelerate the process of bringing regulatory issues towards a productive resolution
   - Provide clear financial building blocks necessary to assess risk and rewards of future operational improvements
EXAMPLE OF AREAS OF FOCUS IN VALUE CREATION WITHIN THE COMMUNITY PROPOSAL

The following details are “in the weeds” but are examples of value questions Glenview has as a shareholder

Legal Synergies

• We understand that members of the HMA Board have communicated that HMA may be spending greater than $60 million per year in legal costs, primarily related to the OIG investigations
• While these costs are depressing the financials used in computing the ongoing future value of HMA, there is no mention of litigation savings in the list of synergies presented in the slide-deck supporting the $150-$180 million of available synergies in the transaction
• To the extent that a Fresh Alternative Board could identify these or other pockets of value, then such increased recurring earnings power could drive greater value for HMA shareholders
• Illustratively, $60 million of EBITDA at an 8.3x EBITDA multiple would be worth $1.85 per share to all HMA shareholders

Strategic Review/Consent Solicitation

• We understand that members of the HMA Board have communicated that HMA may have incurred greater than $25 million of additional expenses associated with HMA’s strategic review and as part of the sitting Board’s participation in the consent solicitation process
• Illustratively, $25m of EBITDA at an 8.3x EBITDA multiple would be worth $0.77 per share to all HMA shareholders

CVR

• In prior Medicare disputes involving large hospital chains, the settlement payments have been a true-up to prior payments, and as such the settlement amounts have been substantially tax deductible
• Assuming the potential 35% deductibility of settlement amounts paid, notwithstanding the $18 million “deductible” feature, the CVR would actually provide Community an economic incentive to pay the MAXIMUM penalty up to the top end of the CVR insurance feature – which would result in a CVR value of $0 and a net of tax cash benefit to Community
• Such a “perverse” outcome may be emblematic of a rushed process and a contract negotiated under duress by the sitting Board

---

1 8.3x EBITDA multiple is used for illustrative purposes as it was set forth by HMA’s sitting Board as an instructive valuation benchmark used in the negotiations. It remains unclear what portion of these 2013 expenditures were included in the LTM numbers.
TWO SEPARATE VOTES ON VALUES

1. In August, all shareholders may vote on the Board, which we believe is a question of principles and values.
2. In December, all shareholders will vote on the Community Proposal and determine if that is the best path to maximize dollar values for shareholders.

Under the Fresh Alternative Board, shareholders can expect:

- A heightened focus on performance, quality, accountability and cost
- A fresh perspective and approach to resolving legacy contingent liabilities harnessing the experience and skills of experts
- Greater financial transparency, and clear financial building blocks for shareholders to properly assess values

Under the supervision of the sitting Board:

- The Board awarded 100-108% performance bonuses to senior executives while the Company clearly missed its guidance to Wall Street in 2012
- The Board approved a management incentive plan that allowed senior executives to get full credit for performance goals despite missing them by a wide margin in 2013 to the extent that a sale of the Company is approved
- The Company published a slide deck on July 25th touting their strong operational and financial performance, five days before materially reducing financial guidance for 2013 and reporting a material miss for the quarter ended June 30th
- In the prior two quarters, in which HMA also missed expectations, the preannounced disappointing results were issued April 9th and January 13th
- This quarter instead, the Company chose to disclose its disappointing operating and financial performance and legal update concurrent with the announcement of the proposed sale of the Company
- Furthermore, rather than hold a public conference call to discuss these critical issues, and to engage in an on the record question and answer session as is customary with such events, the sitting Board chose for its Chairman and members of senior management to meet with a select group of shareholders with a focus on retaining their own Board seats

As public market equity participants, we have an opportunity through this Consent Solicitation to vote our conscience, and to promote not only maximum value, but strong values.
We urge all shareholders to promptly consent to remove and replace the Board to Revitalize HMA

For information on how to vote, please contact
Bruce Goldfarb / Patrick McHugh / Lydia Mulyk at Okapi Partners:
(212) 297-0720 or (877) 869-0171
APPENDIX
A Holistic Approach to Addressing the Current Challenges at HMA

The Fresh Alternative for HMA

Mary Taylor Behrens
- Experience in executive compensation, human resources, succession planning, strategic planning and financial transactions in the healthcare industry

Steven Epstein
- Extensive experience in healthcare law, and service on public, private company and educational institution boards

Kirk Gorman
- Expertise in mergers and acquisitions, corporate finance and corporate governance along with extensive experience as an executive in the hospital industry and on public company boards

Stephen Guillard
- Extensive executive leadership in healthcare services and experience on public and private company boards

John McCarty
- Experience in turn-around situations and financial executive leadership in healthcare and risk assessment services

JoAnn Reed
- Extensive experience as a senior financial executive in healthcare services and service on public and private boards

Steven Shulman – Chairman
- Extensive turn-around experience in the healthcare industry and public and private company board experience

Peter Urbanowicz
- Expertise in regulatory, compliance, financial and turn-around issues facing the healthcare industry, and advisor to multiple boards of directors, management teams, investors and lenders

1. Proven managers, leaders and professionals capable of tackling the myriad of operating, cultural, financial and regulatory issues at HMA

2. Profound healthcare operating and executive experience

3. Strategic insight, capital allocation and financial expertise and appropriate oversight capabilities

4. Human resource, corporate finance, and turn-around and restructuring experience

5. Regulatory and compliance experience in areas germane to HMA
NEW PROPOSED HMA BOARD STRUCTURE AND COMMITTEE COMPOSITION

Steven Shulman
Chairman of the Board

Audit Committee
- John McCarty (Chair)
- Kirk Gorman
- Stephen Guillard

Compensation Committee
- Mary Taylor Behrens (Chair)
- Steven Epstein
- Kirk Gorman
- JoAnn Reed

Compliance & Quality Committee
- Steven Epstein (Chair)
- Stephen Guillard
- John McCarty
- Peter Urbanowicz

Governance Committee
- JoAnn Reed (Chair)
- Mary Taylor Behrens
- Peter Urbanowicz

Note:
1. As Chairman of the Board, Steven Shulman will also serve as an ex officio member of all committees
2. The Compliance & Quality Committee is a newly formed committee that does not currently exist at HMA
Mary Taylor Behrens

Current President of Newfane Advisors, Inc.
Former Head of Merrill Lynch Investment Managers, Americas Region
Board member of Sagent Pharmaceuticals, Inc.

Career Highlights and Experience
- Founded Newfane Advisors, a private consulting firm, in February 2003 and has acted as President since November 2004
- Served as Head or Co-Head of Merrill Lynch Investment Managers, Americas Region from February 2001 to January 2003
- Served as Head of Human Resources and a member of Merrill Lynch & Co.’s Executive Committee from February 1998 to January 2001
- Joined Merrill Lynch in 1989 as an Associate in the Merchant Banking/High Yield Finance and Corporate Finance Groups; subsequently appointed Vice President of the Healthcare Group in 1992, Director in 1995 and Managing Director in 1996
- Joined Chase Manhattan Bank in 1987 as an Associate in the Leverage Lending Group

Board of Directors Experience
- Has served as a member of Sagent Pharmaceuticals, Inc.‘s board of directors since November 2010, Chair of the compensation committee and a member of the corporate governance and nominating committee since November 2010, and a member of the audit committee since 2012
- Served as a member of the compensation and quality committees of the board of directors of HCR ManorCare from November 2004 to December 2007
- Member of the board of the Lawrence Hospital Center
- Served on the board of the YMCA of Greater New York
- Served on the Georgetown Board of Regents for seven years, including five years as the head of its athletic committee

Value Proposition for HMA:
- Detailed knowledge of executive compensation and succession and strategic planning
- Public company human resources experience
- Experience with financial transactions in the healthcare industry
- Service on public company boards
Founder and Senior Health Partner of Epstein Becker & Green, P.C.

Current board member of multiple companies in the healthcare sector

Career Highlights and Experience

- Senior Partner of Epstein Becker & Green, a leading law firm in healthcare law which he founded in 1973
- Provides a wide range of healthcare organizations and providers with strategic legal guidance responding to the legal challenges and opportunities of domestic healthcare
- Amongst many other honors, Chambers USA has ranked Mr. Epstein among the "Leaders in Their Field" in the Healthcare category (2009 to 2013) and has referred to him as the "father of the healthcare [legal] industry." Chambers USA noted in 2012 that Mr. Epstein "is venerated for his ongoing contribution to the development of concepts such as managed care"
- Received Columbia Law School's Medal for Excellence, the school's most prestigious award, in 2009

Board of Directors Experience

- Public and private board experience, including APS Healthcare, Inc., Catalyst Health Solutions, Inc., Catamaran Corp., Discovery Health, Emergency Medical Services Corp., Team Health, MedExpress, Align Networks, Haight Cross Communications and ResCare
- Serves on the board of advisors of Dauphin Ventures and Radius Ventures
- Previously Chairman of Critical Care Solutions
- Nonprofit board membership with Health Insights and Street Law, Inc.
- Chairman of Columbia Law School Board of Visitors
- Former member of the Board of Trustees of Tufts from 1999 to 2009 and currently serves as Director Emeritus

Value Proposition for HMA:

- Extensive experience in healthcare legal issues and government regulation
- Intimate understanding of healthcare organizations and providers
- Service on public and private health care company and educational institution boards
- Expertise in maintaining regulatory compliance
Kirk Gorman

Current Executive Vice President and CFO of Jefferson Health System

Former Senior Vice President and CFO of Universal Health Services

Chairman of the board of CardioNet, Inc.

Career Highlights and Experience

- Currently the Executive Vice President and Chief Financial Officer of Jefferson Health System since September 2003
- Employed by Universal Health Services Inc. from April 1987 to March 2003, where he served as Senior Vice President and Chief Financial Officer (1992 to 2003) and Vice President and Treasurer (1987 to 1992)
- Began his career at Mellon Bank where he became Senior Vice President

Board of Directors Experience

- Chairman of CardioNet, Inc. since October 2011 and a member of the Company’s board since August 2008
- Director and member of the audit committee of IASIS Healthcare, LLC’s board since February 2004
- Served as a Director of Physician’s Dialysis, Inc. and member of the board of HCF Guernsey, Ltd.
- Served as Chairman on the board of Care Investment Trust from June 2007 to October 2009 and as a Trustee of Universal Health Realty Income Trust
- Former board member of VIASYS Healthcare, Inc. from November 2001 to December 2003 and from February 2005 until its acquisition by Cardinal Health in July 2007

Value Proposition for HMA:

- Knowledge of corporate finance and corporate governance
- Acute care and healthcare services mergers and acquisitions expertise
- Extensive experience as an executive in the hospital management industry
- Service on several public and private company boards
Stephen Guillard

Former COO and Executive Vice President of HCR ManorCare, Inc.

Former Chairman, President and CEO of Harborside Healthcare Corp.

Former Co-Founder, President and CEO of Diversified Health Services

Career Highlights and Experience

- Was responsible for HCR ManorCare's $4 billion hospice, home health care and pharmacy, skilled nursing, assisted living and rehabilitation businesses as Executive Vice President (June 2005 to January 2007); later served as the Company's Chief Operating Officer from January 2007 to December 2011
- Served as Chairman, Chief Executive Officer and President of Harborside Healthcare Corporation from 1988 - 2005
- Named by House Speaker John Boehner to serve on a new 15 member, congressionally mandated Commission on Long-Term Care in February 2013

Board of Directors Experience

- Serves as Chairman of The Alliance for Quality Nursing Home Care, a coalition of 18 national provider organizations that care for 650,000 elderly and disabled patients annually and employ approximately 425,000 caregivers nationwide
- Current director of naviHealth, Inc., a provider of post-acute care support solutions
- Previously served on the board of directors of HCR ManorCare, Inc. from 2006 to 2011 and was a member of the Company's quality committee
- Former Chairman of Harborside Healthcare Corporation
- Co-founded and served as Chairman, Chief Executive Officer and President of Diversified Health Services from 1982 to 1988

Value Proposition for HMA:

- Extensive executive and director leadership in post-acute care services and operations
- Service on public and private company boards
- Successful track record in post-acute operations
- Extensive mergers and acquisitions expertise
JOHN MCCARTY

Career Highlights and Experience

- Served as a consultant to Metalmark Capital Holdings, LLC from October 2011 to May 2012
- Served as Executive Vice President and Chief Financial Officer of SHPS, Inc. from February 2006 to December 2009
- Served as Executive Vice President and Chief Financial Officer of LabOne Inc. from April 2000 to March 2005
- Served as Senior Vice President and Chief Financial Officer of eai Healthcare Staffing Solutions, Inc. from January to December of 1999
- Former Chief Financial Officer of United Dental Care from November 1997 to November 1998
- Served as Executive Vice President and Chief Financial Officer of NovaMed Eyecare Services, LLC. from May 1996 to October 1997

Additional Relevant Experience

- Assistant Vice President of Corporate Finance and Vice President of Columbia Capital Corporation for Columbia/HCA prior to 1996; responsible for securing over $7 billion in financing for the company during his tenure
- Served as an investment banking advisor for Healthcare Markets Group
- Served as the Director of Corporate Finance at Humana

Value Proposition for HMA:

- Strong business and financial knowledge
- Experience in turn-around situations
- Diverse financial leadership in the healthcare industry
- Executive experience in risk assessment services
JOANN REED

Current Healthcare Services Consultant

Former Chief Financial Officer of Medco Health Solutions

Director and Audit Committee member of American Tower, Inc.

Career Highlights and Experience

- Served as Chief Financial Officer of Medco Health Solutions from 1996 to March 2008 and as an advisor to the Company’s CEO from April 2008 to April 2009
- Joined Medco Containment Services, Inc. (Medco Health Solutions’ predecessor) in 1988 as Director of Financial Planning and Analysis; appointed as the Senior Vice President of Finance for Medco in 1992 and as Chief Financial Officer in 1996
- Served in various financial roles with Aetna/American Re-insurance Co., CBS Inc., Standard and Poor’s, and Unisys/Timeplex Inc. prior to joining Medco

Board of Directors Experience

- Appointed as a Director and Chair of the Audit Committee of Mallinckrodt Pharmaceuticals in June 2013
- Director and member of the Audit Committee of American Tower, Inc. since May 2007
- Director and member of the Audit Committee of Waters Corporation since May 2006
- Trustee for St. Mary’s College of Notre Dame
- Former Director at Dynavox Inc. from April 2010 to December 2012

Value Proposition for HMA:

- Extensive experience as a financial executive in the healthcare industry
- Deep accounting skillset gained from service on public company audit committees
- Service on public and private boards
- Corporate executive advisory expertise
STEVEN SHULMAN

Senior Advisor of Water Street Healthcare Partners

Former Chairman, Chief Executive Officer of Magellan Health Services

Former Chairman, President and CEO of Prudential Healthcare Inc.

Career Highlights and Experience

- Current Managing Partner at Shulman Ventures
- Served as CEO of Magellan Health Services, Inc. from November 2002 to February 2008 where he aided in the company's successful turn-around and restructuring from bankruptcy
- Founder, Chairman and CEO at Internet Healthcare Group from 2000 to 2002
- Led Prudential Healthcare's corporate turn-around during his tenure as the company's Chairman, President and CEO from 1997 to 1999, culminating in the company's successful sale to Aetna
- Co-founded Value Health, Inc. in 1987 and served with the company until 1997
- Served in leadership positions at Cigna from 1983 to 1987 and at Kaiser Permanente

Board of Directors Experience

- Serves on the board of directors of Accretive Health, Inc., Facet Technologies, HealthMarkets, HealthPlan Holdings, aTherapy and Oasis Outsourcing
- Chairman of Access MediQuip since 2009, CareCentrix since 2008 and Digital Insurance
- Former Chairman at Lumenos, Inc. and former Vice Chairman at BenefitPoint, Inc. since 2001
- Former Director at InteCardia, Inc., Respironics Novametrix, LLC., Premier Behavioral Solutions, Inc., Onehealthbank.com, Precyse Solutions, LLC and The Broadlane Group, Inc.
- Former member of the Strategic Advisory Board at Satori World Medical, Inc.

Value Proposition for HMA:

- Executive turn-around experience in the healthcare industry
- Senior management expertise and operational and transaction experience
- Extensive private and public board service
- Recognized for his leadership including being named one of the top CEOs in the managed care industry by Institutional Investor
Peter Urbanowicz

Managing Director at Alvarez & Marsal's Healthcare Group
Former Executive VP, General Counsel and Secretary of Tenet Healthcare
Former Deputy General Counsel of Dept. of Health and Human Services

Career Highlights and Experience

- Has led Alvarez & Marsal's healthcare compliance practice since May 2008 and has more than 20 years of experience addressing healthcare issues in government and private industry
- Resolved major federal criminal investigations and civil lawsuits facing Tenet Healthcare by the U.S. Department of Justice, the SEC and the HHS Office of Inspector General during his tenure at the Company from January 2004 to March 2008
- Served as Deputy General Counsel of the U.S. Department of Health and Human Services from October 2001 to December 2003, and was a member of the team that drafted the Medicare Prescription Drug Act of 2003
- Prior to 2001, served as a partner in the law firm of Locke, Liddell & Sapp

Board of Directors Experience

- Serves on the board of directors of Maxim Healthcare Services, one of the nation's largest home health services companies; chairman of the Company's compliance committee
- Regularly advises boards of directors facing significant regulatory, financial or operating challenges in the healthcare industry

Value Proposition for HMA:

- Expertise in regulatory, compliance, financial and operating issues facing the healthcare industry
- Consistent advisor to boards of directors, senior management, investors and lenders
- Turn-around experience and guidance on operational and financial improvement
- Healthcare services board experience

Cautionary Statement Regarding Forward-Looking Statements
This presentation may include “forward-looking statements” that reflect current views of future events. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature are often used to identify forward-looking statements. Similarly, statements that describe our objectives, plans or goals are forward-looking. Glenview’s forward-looking statements are based on its current intent, belief, expectations, estimates and projections regarding the Company and projections regarding the industry in which it operates. These statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to differ materially. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Except to the extent required by applicable law, no person undertakes any obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.